Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
第一作者:
Toni K,Choueiri
第一单位:
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
作者:
主题词
人类(Humans);癌, 肾细胞(Carcinoma, Renal Cell);男(雄)性(Male);女(雌)性(Female);肾肿瘤(Kidney Neoplasms);喹啉类(Quinolines);中年人(Middle Aged);老年人(Aged);苯脲化合物(Phenylurea Compounds);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);成年人(Adult)
DOI
10.1016/S0140-6736(24)01758-6
PMID
39284329
发布时间
2025-01-02
- 浏览0

Lancet (London, England)
1309-1320页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文